Table 1.
Baseline characteristics of baseline Tunisian DTC survivors’ characteristics.
| Tunisian DTC survivors'Characteristics | Variables |
|---|---|
| Total DTC survivors | N=86 |
| Age at diagnosis (yr), mean (±SD) | 38.5 (± 12.4) |
| Age at evaluation (yr), mean (±SD) | 44.3 (± 12.5) |
| Survivorship (yr), mean (±SD) | 5.8 (± 4.8) |
| Gender | |
| Male, n(%) | 9 (10.5%) |
| Female, n(%) | 77 (89.5%) |
| Menopausal women, n(%) | 27 (34.6%) |
| Education | |
| Primary school degree, n(%) | 31 (36%) |
| High school degree, n(%) | 33 (38.4%) |
| University degree, n(%) | 22 (25.6%) |
| Profession | |
| Unemployed, n(%) | 17 (19.8%) |
| Blue-collar worker, n(%) | 60 (69.8%) |
| White-collar worker, n(%) | 9 (10.5%) |
| Nombre of comorbidities | |
| None, n(%) | 56 (65.5%) |
| 1, n(%) | 14 (16.3%) |
| ≥ 2, n(%) | 16 (18.6%) |
| DTC pathology | |
| Papillary thyroid carcinoma, n(%) | 79 (91.9%) |
| Follicular thyroid carcinoma, n(%) | 7 (8.1%) |
| Unifocal DTC, n(%) | 33 (38.3%) |
| Multifocal DTC, n(%) | 43 (61.7%) |
| Microcarcionoma, n(%) | 30 (34.9%) |
| T stage | |
| pT1, n(%) | 48 (55.8%) |
| pT2, n(%) | 15 (17.4%) |
| pT3, n(%) | 19 (22.1%) |
| pT4, n(%) | 2 (2.3%) |
| Unknown, n(%) | 2 (2.3%) |
| Cervical lymph node metastases | |
| pN0, n(%) | 45 (52.3%) |
| pN+, n(%) | 41 (47.7%) |
| Distant Metastases | |
| M0, n(%) | 80 (93%) |
| M+, n(%) | 6 (7%) |
| ATA risk category | |
| Low-risk DTC, n(%) | 30 (34.9%) |
| Intermediate-risk DTC, n(%) | 37 (43%) |
| High-risk DTC, n(%) | 19 (22.1%) |
| Management protocol | |
| Total thyroidectomy, n(%) | 86 (100%) |
| pCNL , n(%) | 86 (100%) |
| RAI remanant ablation, n(%) | 86 (100%) |
| RAI cumulative dose (mCi), mean (±SD) | 274.4 (± 249.7) |
| TSH suppression therapy, n(%) | 86 (100%) |
| TSH level at evaluation (mIU/L), mean (±SD) | 0.42 (± 0.86) |
DTC, Differentiated thyroid cancer; ATA, American Thyroid Association; pCNL, prophylactic central neck lymphadenectomy; RAI, radioactive iodine 131; TSH, Thyroid-stimulating hormone.